Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.39 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.39 |
| ▸ | PKM | P14618 | 2/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 5/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | PYGL | P06737 | 4/20 | 0.36 |
| ▸ | DHODH | Q02127 | 5/20 | 0.35 |
| ▸ | NPC1 | O15118 | 4/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.33 |
| ▸ | TCF7L2 | Q9NQB0 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20560749 | 1.00 | GAA (0.39) | GAAKEAP1NFE2L2PKMMAPK1 | |
| SCHEMBL29742278 | 1.00 | GAA (0.39) | GAAKEAP1NFE2L2PKMMAPK1 | |
| SCHEMBL28559681 | 0.92 | DHODH (0.40) | GAAKEAP1NFE2L2PKMMAPK1 | |
| SCHEMBL28562623 | 0.91 | GAA (0.39) | GAAKEAP1NFE2L2PKMMAPK1 | |
| SCHEMBL24455254 | 0.90 | DHODH (0.37) | GAAKEAP1NFE2L2PKMMAPK1 | |
| SCHEMBL28574410 | 0.90 | DHODH (0.38) | GAAKEAP1NFE2L2PKMMAPK1 | |
| SCHEMBL28576661 | 0.90 | DHODH (0.38) | GAAKEAP1NFE2L2PKMMAPK1 | |
| SCHEMBL28563781 | 0.90 | DHODH (0.38) | GAAKEAP1NFE2L2PKMMAPK1 | |
| SCHEMBL25665425 | 0.90 | KEAP1 (0.39) | GAAKEAP1NFE2L2PKMMAPK1 | |
| SCHEMBL20560768 | 0.89 | PKM (0.37) | GAAPKMMAPK1RAB9ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3883579-B1 | COMBINATION THERAPY INCLUDING A KRAS-G12C INHIBITOR AND ONE OR MORE ADDITIONAL PHARMACEUTICALLY ACTIVE AGENTS FOR THE TREATMENT OF CANCERS | AMGEN INC (US) | 2025-12-24 | — | — | EP | disclosed |
| US-20250206736-A1 | SYNTHESIS OF KRAS G12C INHIBITOR COMPOUND | AMGEN INC. (US) | 2025-06-26 | — | — | US | disclosed |
| CN-114728960-B | Improved synthesis of KRAS G12C inhibitor compounds | 美国安进公司 | 2025-05-27 | — | — | CN | disclosed |
| CN-119638693-A | Improved synthesis of key intermediates for KRAS G12C inhibitor compounds | 美国安进公司 | 2025-03-18 | — | — | CN | disclosed |
| CN-119638694-A | Improved synthesis of key intermediates for KRAS G12C inhibitor compounds | 美国安进公司 | 2025-03-18 | — | — | CN | disclosed |
| CN-113015724-B | Improved synthesis of key intermediates for KRAS G12C inhibitor compounds | 美国安进公司 | 2025-02-18 | — | — | CN | disclosed |
| US-20240408093-A1 | HETEROBIFUNCTIONAL COMPOUNDS AND THEIR USE IN TREATING DISEASE | HALDA THERAPEUTICS OPCO, INC. | 2024-12-12 | — | — | US | disclosed |
| CN-113038953-B | Including KRAS for the treatment of cancerG12CCombination therapy of an inhibitor and one or more other pharmaceutically active agents | 美国安进公司 | 2024-08-23 | — | — | CN | disclosed |
| WO-2023059609-A1 | HETEROBIFUNCTIONAL COMPOUNDS AND THEIR USE IN TREATING DISEASE | HALDA THERAPEUTICS OPCO, INC. (US) | 2023-04-13 | — | — | WO | disclosed |
| WO-2023059605-A1 | HETEROBIFUNCTIONAL COMPOUNDS AND THEIR USE IN TREATING DISEASE | HALDA THERAPEUTICS OPCO, INC. (US) | 2023-04-13 | — | — | WO | disclosed |
| EP-4058453-A1 | IMPROVED SYNTHESIS OF KRAS G12C INHIBITOR COMPOUND | Amgen Inc. (US) | 2022-09-21 | — | — | EP | disclosed |
| CN-114907259-A | Synthetic method of Sotolira intermediate | 常州中氪生命科学技术有限公司 | 2022-08-16 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240408093-A1 | HETEROBIFUNCTIONAL COMPOUNDS AND THEIR USE IN TREATING DISEASE | FGFR3, FGFR1, ERBB3 | GAA 3195/4885KEAP1 998/4885NFE2L2 2601/4885 |
| US-20250206736-A1 | SYNTHESIS OF KRAS G12C INHIBITOR COMPOUND | KRAS, NRAS, HRAS | GAA 3275/4885KEAP1 602/4885NFE2L2 1596/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.